Adaptive Biotechnologies (ADPT) EBIT Margin (2018 - 2026)
Adaptive Biotechnologies (ADPT) posted EBIT Margin of 27.1% for Q1 2026, down 52.08% sequentially from 17.82% in Q4 2025, and up 2935.0% YoY from 0.89% in Q1 2025.
Adaptive Biotechnologies (ADPT) EBIT Margin (2018 - 2026) Analysis & Trends
Adaptive Biotechnologies has reported EBIT Margin for 9 years, with the latest figure at 27.1% in Q1 2026.
- Quarterly EBIT Margin rose 2935.0% year-over-year to 27.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.82% (up 5984.0% YoY) and the FY2025 annual result came in at 20.62%, up 7021.0% from the prior year.
- EBIT Margin slipped to 27.1% in Q1 2026 per ADPT's latest filing, from 17.82% in the prior quarter.
- Over five years, EBIT Margin peaked at 10.95% in Q3 2025 and troughed at 621.01% in Q2 2023.
- A 5-year average of 118.39% and a median of 94.98% in 2022 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2023 and 2024: EBIT Margin plunged 50076 bps in 2023, then soared 51146 bps in 2024.
- Over 5 years, EBIT Margin stood at 70.99% in 2022, then plunged by 119 bps to 155.22% in 2023, then surged by 54 bps to 71.3% in 2024, then soared by 75 bps to 17.82% in 2025, then sank by 52 bps to 27.1% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 27.1%, 17.82%, and 10.95% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 17.99% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 34.98% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 21.74% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 11.58% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -13.42% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 21.14% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 31.97% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.08% |
| 10 | Adaptive Biotechnologies | 3.80 Bn | 3.58 Bn | 52.17 Mn | -27.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.10% |
| Dec 31, 2025 | -17.82% |
| Sep 30, 2025 | 10.95% |
| Jun 30, 2025 | -42.52% |
| Mar 31, 2025 | -56.45% |
| Dec 31, 2024 | -71.30% |
| Sep 30, 2024 | -70.27% |
| Jun 30, 2024 | -109.56% |
| Mar 31, 2024 | -116.45% |
| Dec 31, 2023 | -155.22% |
| Sep 30, 2023 | -134.38% |
| Jun 30, 2023 | -621.01% |
| Mar 31, 2023 | -151.92% |
| Dec 31, 2022 | -70.99% |
| Sep 30, 2022 | -94.98% |
| Jun 30, 2022 | -120.25% |
| Mar 31, 2022 | -163.30% |
| Dec 31, 2021 | -162.39% |
| Sep 30, 2021 | -142.71% |
| Jun 30, 2021 | -129.24% |